NCT06054698

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Overweight or Obese Subjects

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy of HRS9531 injection compared with placebo in weight reduction in overweight or obese subjects after 36 weeks of treatment.

Conditions

• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	HRS9531 injection	HRS9531 injection , QW，36 weeks
DRUG	HRS9531 injection Placebo	HRS9531 injection Placebo，QW，36 weeks

Timeline

• Start date: 2023-10-01
• Primary completion: 2024-08-01
• Completion: 2024-09-01
• First posted: 2023-09-26
• Last updated: 2023-09-26